All Boards >> Irritable Bowel Syndrome Research Library

View all threads Posts     Flat     Threaded

Enteric Bacteria and IBS
      11/26/06 02:51 PM

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Advances in Functional Gastrointestinal Disorders -- Enteric Bacteria and IBS

Brooks D. Cash, MD, FACP, FACG
Las Vegas, Nevada; Monday, October 23, 2006 --

The functional gastrointestinal disorders (FGIDs), chief among them the irritable bowel syndrome (IBS), are extremely common reasons for seeking healthcare and can be extremely frustrating to patients and clinicians because of the lack of a reliably identifiable pathophysiologic etiology and an even less reliable response to therapy. Considered by many as heterogeneous disorders with a variety of organic and psychological causes, the FGIDs have been the topic of a great deal of groundbreaking research and clinical developments over the last several years. In IBS, organic abnormalities such as abnormal serotonin signaling and homeostasis, altered densities of inflammatory cells and humoral inflammatory mediators, and disturbed visceral proprioception and central processing of pain have all been demonstrated in select groups of patients. More recently, significant attention has been directed toward clarifying the role of intestinal bacteria in the evolution of IBS symptoms. The recognition of postinfectious IBS as a common sequel of acute infectious gastroenteritis,[1] in addition to data demonstrating prevalence values of small intestinal bacterial overgrowth (SIBO) between 30% and 70% in patients with IBS, is driving forward research into the fields of probiotic therapy as well as antibiotic therapy to ease IBS symptoms.[2,3] This report highlights the research in this area, as presented on Monday, October 23, 2006, at the annual scientific meeting of the American College of Gastroenterology (ACG).

Diagnosing SIBO in IBS

The typical methods involved in diagnosing SIBO are breath-test measurements of expired gases after a sugar load (most commonly glucose or lactulose) or small bowel fluid aspiration and culture. The prevalence of SIBO diagnosed via breath testing rages from 10% to as high as 84% in the literature.[4,5] Breath testing can be difficult to perform because of the strict requirements for patient compliance and, in the case of glucose breath testing, variability in the absorption of glucose. Similarly, the gold standard, jejunal aspirate and culture, is limited by the invasiveness of the procedure and the anatomic extent of aspirating tube advancement, usually to the proximal 40-60 cm of the small intestine. Several investigators reported their experience with each of these diagnostic techniques during this year's ACG meeting. Bratten and colleagues[6] from Northwestern University in Chicago, Illinois, performed lactulose breath testing (for hydrogen [H+] and methane [CH4+]) in 175 patients with IBS and 23 non-IBS controls. They found that 21% (37/175) of the IBS patients produced CH4+ compared with 9% (2/23) of controls (P = .16). They also found that patients who had CH4+-positive breath tests were more than twice as likely as CH4+-negative IBS patients to have constipation as their predominant stool pattern (odds ratio [OR] = 2.61; 95% confidence interval [CI]: 1.24-5.54; P = .01) and were significantly less likely to have diarrhea (OR = 0.28; 95% CI: 0.13-0.63; P = .001). The observation that CH4+-positive breath tests correlate with constipation has been made by other investigators, but the mechanisms underlying the association between CH4+ and constipation remain poorly understood.[7]

Ruff and colleagues[8] from the Mayo Clinic College of Medicine in Rochester, Minnesota, reported the results of a retrospective analysis of clinical parameters and results of duodenal aspirate culture in 690 patients. Using the criteria of > 100,000 colony-forming units (cfu)/mL of aspirate for the diagnosis of SIBO, these investigators failed to detect an increased prevalence of SIBO in patients with diagnosed IBS or the symptom of bloating. These results contrast with previous reports using less restrictive cfu/mL criteria for the diagnosis of SIBO, and should be viewed cautiously. Potential pitfalls in this analysis include that many of the patients were taking narcotics, a systematic program of aspiration in patients with IBS was not undertaken, and the duodenal aspirates may not be adequate to rule out distal SIBO.

Bacterial Overgrowth -- Is it Hype or Hope?

During a clinical symposium convened during this year's ACG meeting, leading experts in the field addressed issues surrounding the diagnosis of SIBO and the use of antibiotics and probiotics.[9-11] Dr. Jack DiPalma[9] opened the symposium with a discussion of bacterial overgrowth. He highlighted some of the clinical conditions that predispose patients to bacterial overgrowth, such as postsurgical states, age extremes, and motility abnormalities, as well as the symptoms of overgrowth such as chronic diarrhea, malabsorption, and nutrient deficiencies. He touched on the various diagnostic tests for bacterial overgrowth and identified the best predictive factors among these tests: fasting elevations in H+ or CH4+, a positive 14C D-xylose test, or jejunal culture with > 105 cfu/mL. Dr. DiPalma also discussed the well-known limits of the so-called "gold standard" of small bowel fluid aspiration and culture, which include the invasive nature of the test, oral floral contamination, culture transport difficulties, limited access to the distal small bowel, and the unclear relevance of colonization in the elderly. He concluded by reviewing the ideal testing measures that should be present when testing for bacterial overgrowth. These include measuring both H+ and CH4+, using a standard dose of breath-test substrate, confirming the fasting state of patients undergoing testing when fasting elevations are found during fructose or glucose testing, and the need to test before a colon cleansing (or waiting for at least 30 days after a colon cleansing to test).

Dr. Lawrence Schiller[10] followed with a discussion of prebiotics and probiotics. It is interesting to note that there are more than 1015 bacteria in the human gut, of which 500 different species have been identified and one third have been cultured. In comparison, the average human body contains approximately 1014 cells. The bacteria have been selected, through the innate immune system (that part of the immune system that responds to immunogenic patterns rather than specific antigens), to coexist in the gut and provide for enterocyte nutrients, vitamin production, defense against pathogenic bacteria, and to modulate mucosal inflammation and permeability. Prebiotics are substances that can be ingested and which foster bacterial growth, and include fructo-oligosaccharides, inulin, and lactulose. Very few data exist regarding the role of prebiotics as therapies for IBS. The probiotics are live organisms that can be ingested for health benefits, but there is little theoretical basis for the selection of particular strains of probiotics, and the exact contributions of probiotics to intestinal health are unknown. Examples of probiotics include Lactobacillus and Bifidobacterium species and Escherichia coli Nissle 1917. Yeasts such as Saccharomyces species can also be used as probiotic therapy. Potential mechanisms of action for probiotics include displacement of pathogens, enhancement of bacterial function, and modification of signaling. Although complications of probiotic therapy are rare and some mixtures have been reported to improve IBS symptoms, many unanswered questions remain. These include whether live organisms need to be ingested, whether enteric colonization occurs, the ideal duration of therapy, and what biochemical signatures are most predictive of treatment success.

Dr. Mark Pimentel[11] concluded the symposium with a discussion of the rationale for the use of antibiotics in IBS. He eloquently presented the evidence for the role of enteric bacteria in the etiology of IBS symptoms and how intrinsic or extrinsic factors can produce alterations in the normal motility pattern of the gut, leading to abnormal levels of enteric bacteria which then induce inflammation and/or further alterations in gut function through the elaboration of H+ and/or CH4+. Dr. Pimentel then reviewed the evidence supporting the use of antibiotics, often in combination with promotility agents such as tegaserod, for the effective treatment of IBS. The promotility agents are used to promote more effective peristalsis and intestinal stripping waves and may have a role in preventing recurrence, although this concept has not been studied rigorously. When used for this purpose, tegaserod is usually administered at a lower dose (2 mg) and in a fasting state (every night at bedtime) rather than the standard regimen used in the settings of IBS with constipation and chronic constipation (6 mg twice daily) in order to minimize potential motility-related side effects such as diarrhea. Although it is clear that there is much that we do not know regarding the role and effects of modulation of the enteric flora in patients with IBS, this is a very exciting corner of the IBS world and additional data are eagerly awaited.

One of the overarching concerns surrounding the use of probiotics is their safety. In another abstract presented during this meeting, Adler and colleagues[12] reported results of a safety study evaluating the effects of the probiotic E coli strain M-17 in 138 healthy individuals. Subjects ingested 120 mL/day of E coli strain M-17 every day for 8 weeks, a dose that represents a 10-fold increase over standard dosing regimens. The M-17 was generally well tolerated, with associated adverse events seen in 6.5% of patients, most of which were mild. Multiple laboratory parameters were followed, and although there were some changes from baseline, all laboratory values remained within normal limits. Additional clinical data reflecting effects on symptoms in patients with IBS are eagerly awaited.

Concluding Remarks
The field of FGIDs continues to generate meaningful and important research. Emerging data surrounding the role of enteric bacteria in the origin of IBS symptoms are among the hottest topics in this field. During this year's ACG meeting, excellent overviews and original research were presented regarding the yield of diagnostic maneuvers for the detection of SIBO and the various treatment approaches to IBS involving the manipulation of the intestinal flora; such data will no doubt add to this controversial growing body of literature.

Halvorson H, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome--a meta-analysis Am J Gastroenterol. 2006;101:1-6.
Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581-1590. Abstract
Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-563. Abstract
Harris LA, Crowell MD, DiBaise JK, et al. Is small intestinal bacterial overgrowth (SIBO) really prevalent in irritable bowel syndrome (IBS)? Am J Gastroenterol. 2005;100:S336.
Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-419. Abstract
Bratten J, Spanier J, Jones MP Lactulose hydrogen breath testing (LHBT) in patients with IBS and controls: differences in methane (CH4) but not hydrogen (H2). Am J Gastroenterol. 2006;101;S479. [Abstract 1236]
Pimental M, Lin H, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1089-G1095. Abstract
Ruff KC, Saio-Loftus YA, Locke GR, et al. Failure to detect association with irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). Am J Gastroenterol. 2006;101;S486. [Abstract 1261]
DiPalma JA. Diagnosis and treatment of bacterial overgrowth. In: ACG Clinical Symposium: Bacterial Overgrowth: Hype or Hope. Program and abstracts of the American College of Gastroenterology 2006 Annual Scientific Meeting and Postgraduate Course; October 20-25, 2006; Las Vegas, Nevada.
Schiller LR. Prebiotics and probiotics. In: ACG Clinical Symposium: Bacterial Overgrowth: Hype or Hope. Program and abstracts of the American College of Gastroenterology 2006 Annual Scientific Meeting and Postgraduate Course; October 20-25, 2006; Las Vegas, Nevada.
Pimentel M. IBS: Is SBO really a factor? In: ACG Clinical Symposium: Bacterial Overgrowth: Hype or Hope. Program and abstracts of the American College of Gastroenterology 2006 Annual Scientific Meeting and Postgraduate Course; October 20-25, 2006; Las Vegas, Nevada.
Adler SN, Jacob H, Levine L. An open label, high dose prospective trial of the safety of the probiotic E. coli strain M-17 in healthy volunteers. Am J Gastroenterol. 2006;101:S134. [Abstract 273]

Copyright 2006 Medscape.

Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Entire thread
* Pharmaceutical
07/14/03 01:50 PM
* Medical Marijuana Significant for Migraines, Fibromyalgia, and IBS
02/16/21 01:21 PM
* Heartburn drugs that are proton pump inhibitors could trigger IBS and SIBO
12/07/20 01:28 PM
* For IBS Patients, Cannabis Linked to Fewer Rehospitalizations
05/05/20 02:14 PM
* Cannabis could help a person defecate
04/14/20 12:17 PM
* FDA OKs Reintroduction of Tegaserod (Zelnorm) for IBS-C in Women Under 65
04/04/19 02:45 PM
* Long-term cannabis use increases risk for IBS
10/19/17 04:04 PM
* FDA approves new drug for chronic constipation
01/26/17 03:05 PM
* Mixed Opioid Agent Adds to Growing List of Therapies for IBS-D
01/27/16 02:48 PM
* Low-dose naltreoxone for the treatment of irritable bowel syndrome
01/26/16 01:20 PM
* Amitiza benefited patients with chronic idiopathic constipation
02/10/15 04:15 PM
* Medical Marijuana for Digestive Disorders: High Time to Prescribe?
09/17/14 02:08 PM
* Antibiotics Early in Life May Boost Obesity Risk
08/18/14 03:13 PM
* Antidepressants, psychological therapies effectively treated IBS
07/15/14 02:49 PM
* Proton pump inhibitor (acid reflux drugs) may cause heart disease
09/23/13 03:22 PM
* Older drugs are better than new ones
06/13/13 02:00 PM
* On Anti-Depressants? Some Raise Risk of C. Diff Infection
05/13/13 05:51 PM
* Heartburn drugs, NSAID painkillers use linked to IBS symptoms
03/18/13 01:24 PM
* FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation
08/31/12 11:25 AM
* 3-month FDA delay for potential IBS drug linaclotide
04/23/12 01:45 PM
* Latest FDA watch list includes GI drugs
04/23/12 01:42 PM
* Antibiotics that reduce gut bacteria linked to obesity
05/06/11 12:25 PM
* Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
02/10/11 10:23 AM
* Antacids increase risk of pneumonia
01/14/11 04:35 PM
* Editorial - Antibiotic Rifaximin (Xifaxan) Therapy for the Irritable Bowel Syndrome
01/07/11 03:01 PM
* Antiobiotic Rifaximin (Xifaxan) for Patients with Irritable Bowel Syndrome without Constipation
01/07/11 02:59 PM
* Proton Pump Inhibitor Drugs Tied to 80% Increase in Clostridium difficile Risk
11/10/10 11:29 AM
* Phase 3 clinical trials of linaclotide for IBS constipation
10/13/10 02:44 PM
* An over-the-counter drug for constipation offers superior symptom relief compared with a commonly used prescription agent
07/16/10 03:17 PM
* Benefit/risk ratio of Renzapride not sufficient to warrant further study in IBS-C
04/07/10 01:32 PM
* Adverse effects of drugs on small intestine and colon
03/16/10 11:23 AM
* Children's Belly Aches Don't Disappear With Antidepressant
03/11/10 01:14 PM
* Survey: Marijuana Use In Patients With IBS
01/12/10 03:17 PM
* FDA Approves Amitiza for IBS-C
05/23/08 10:59 AM
* Zelnorm no longer available except for emergency use
04/11/08 12:05 PM
* Clinical trial: phase 2 trial of lubiprostone for irritable bowel syndrome with constipation.
02/15/08 11:20 AM
* Role of Antibiotics vs Conventional Pharmacotherapy in Treating Symptoms of Irritable Bowel Syndrome
01/03/08 04:45 PM
* FDA permits the restricted use of Zelnorm
08/09/07 11:41 AM
* Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome
06/20/07 01:56 PM
* Neuromuscular Dysfunction and IBS: Clinical Implications for Drug Use
02/04/07 04:30 PM
* Enteric Bacteria and IBS
11/26/06 02:51 PM
* Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS
11/26/06 02:39 PM
* Antibiotic Rifaximin Appears Safe and Effective for Irritable Bowel Syndrome
10/26/06 10:29 AM
* Citalopram (Celexa) Improves Symptoms of Irritable Bowel Syndrome
10/14/06 12:57 PM
* Marijuana eases chronic pain
07/17/06 11:49 AM
* Doctors group launches war on drug ads
07/17/06 11:17 AM
* New IBS drug in development in Japan
07/05/06 05:13 PM
* Marijuana and the gastrointestinal tract
06/12/06 03:38 PM
* Zelnorm Rejected Again in Europe
04/02/06 03:25 PM
* Antidepressants for IBS
03/16/06 12:31 PM
* Takeda Laxative Wins U.S. Approval for Adults
02/18/06 01:36 PM
* Cilansetron: ; Solvay Pharmaceuticals suspends registration activites in the U.S.,
01/18/06 04:15 PM
* Hearburn Drugs Cause Diarrhea
01/08/06 05:10 PM
* Zelnorm fails to win EU panel backing
12/21/05 11:25 AM
* Non-steroidal anti-inflammatory drugs and gastrointestinal damage
12/08/05 12:51 PM
* Octreotide May Be Effective in Treatment of Nonconstipated IBS
12/08/05 12:31 PM
* Lack of Lasting Effectiveness of Miralax Laxative Treatment of Constipation.
08/07/05 04:18 PM
* Acute Hepatitis Associated With Lotronex
07/24/05 02:37 PM
* FDA revisions to safety labeling for Lotronex (alosetron )
05/22/05 06:46 PM
* Clinical pharmacology of new motility promoting agents
05/22/05 06:33 PM
* Rationale for Using Serotonergic Agents to Treat Irritable Bowel Syndrome
05/08/05 06:21 PM
* Zelnorm Associated With Rare Cases of Severe Diarrhea, Ischemic Colitis
04/24/05 03:48 PM
* Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders not Related to Dosage
03/28/05 01:32 PM
* Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS
02/19/05 05:56 PM
* Irritable Bowel Syndrome Medications Side Effects Survey
11/09/04 02:04 PM
* On the Relationship Between Colon Ischemia, Irritable Bowel Syndrome, and Serotonergic Therapy of Irritable Bowel Syndrome
10/24/04 07:10 PM
* New Risk Information on Zelnorm for IBS for Women
07/11/04 02:18 PM
* The Relationship among Previous Antimicrobial Use and H. Pylori Infections
06/27/04 01:33 PM
* Therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome
06/04/04 03:54 PM
* Pharmaceutical companies funding a number of studies into IBS in the UK
05/25/04 12:00 PM
* Irritable bowel syndrome helped by Paroxetine, a drug for depression
05/10/04 02:15 PM
* Fears cause low sales of Lotronex
05/10/04 01:46 PM
* Zelnorm Warning Issued by FDA
05/10/04 01:01 PM
* Renzapride Improves Symptoms in Constipation-Predominant Irritable Bowel Syndrome
12/01/03 06:14 PM
* Clinical Trial Guidelines for Pharmacological Treatment of IBS - Pharmacological Options
12/01/03 05:55 PM
* SOLVAY presses ahead with cilansetron, a new IBS drug
11/18/03 03:43 PM
* Measuring Treatment Effects in IBS Trials
10/20/03 03:30 PM
* FDA Orders Novartis To Pull Zelnorm Ads
10/07/03 11:25 PM
* Step-down dosage of PPI drugs for hearburn
09/30/03 01:26 PM
* Evaluation of drug treatment in irritable bowel syndrome
09/30/03 12:52 PM
* Pain Relievers and Intestinal Disorders
09/16/03 04:20 PM
* Hypersensitivity and hyperreactivity in IBS: opportunity for drug discovery
07/18/03 12:39 PM
* Antidepressants in the Treatment of IBS and Other Functional GI Disorders
07/18/03 12:20 PM
* Use of Antidepressants in the Treatment of IBS?
07/14/03 03:58 PM
* Combined use of SSRIs and NSAIDs increases the risk of GI adverse effects
07/14/03 03:15 PM

Extra information
0 registered and 75 anonymous users are browsing this forum.

Moderator:  Heather 

      You cannot post until you login
      You cannot reply until you login
      HTML is enabled
      UBBCode is enabled

Thread views: 496672

Jump to

| Privacy statement Help for IBS Home

UBB.threads™ 6.2 BBB Business Review